ATHERSYS, INC / NEW

CLEVELAND, OH How do I update this listing?

Athersys, INC / NEW is based out of Cleveland. Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes ATHX-105, a Phase I clinical trial product for the treatment of obesity. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders that include sleep disorders, such as narcolepsy or excessive daytime sleepiness; and other potential indications, such as attention deficit hyperactivity disorder and other cognitive disorders. In addition, Athersys, through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for bone marrow transplant/oncology support, ischemic stroke, and other disease indications.Whalewisdom has at least 143 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2012-03-22. The notice included securities offered of Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Create Alert

Contact Info

athersys, inc / new
3201 CARNEGIE AVENUE
CLEVELAND OH    44115-2634

Business Phone: 216-431-9900
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2012-03-22 D BIOTECHNOLOGY Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 18,000,004 9,000,002 9,000,002
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
GEORGE M. MILNE subscription required
    DIRECTOR
GIL VAN BOKKELEN subscription required
    EXECUTIVE OFFICER DIRECTOR
ISMAIL KOLA subscription required
    DIRECTOR
JACK L. WYSZOMLERSKI subscription required
    DIRECTOR
JOHN J. HARRINGTON subscription required
    EXECUTIVE OFFICER DIRECTOR
LAURA K. CAMPBELL subscription required
    EXECUTIVE OFFICER
LEE E. BABISS subscription required
    DIRECTOR
LORIN J. RANDALL subscription required
    DIRECTOR
WILLIAM LEHMANN subscription required
    EXECUTIVE OFFICER

Elevate your investments